Evidence map›Paper›PMID 28369685›Full record

ArticleBritish journal of pharmacology2017

Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism.

Samuel Chao Ming Yeo, Peter S Fenwick, Peter J Barnes, Hai Shu Lin, Louise E Donnelly

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
10.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Senotherapy for chronic lung disease.Pharmacological reviews · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. UnripeNutrients · 2023
    Article
  13. The Potential of Stilbene Compounds to Inhibit MCurrent issues in molecular biology · 2022
    Article
  14. Article
  15. Article
  16. Polyphenols, flavonoids and inflammasomes: the role of cigarette smoke in COPD.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Samuel Chao Ming YeoAirway Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Peter S FenwickAirway Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Peter J BarnesAirway Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Hai Shu LinDepartment of Pharmacy, Faculty of Science, National University of Singapore, Singapore.
Louise E DonnellyAirway Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Imperial College London · GBNational University of Singapore · SGLung Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeChronic obstructive pulmonary disease (COPD) is a corticosteroid-resistant airway inflammatory condition. Resveratrol exhibits anti-inflammatory activities in COPD but has weak potency and poor pharmacokinetics. This study aimed to evaluate the potential of isorhapontigenin, another dietary polyphenol, as a novel anti-inflammatory agent for COPD by examining its effects in vitro and pharmacokinetics in vivo. EXPERIMENTAL APPROACH: Primary human airway epithelial cells derived from healthy and COPD subjects, and A549 epithelial cells were incubated with isorhapontigenin or resveratrol and stimulated with IL-1β in the presence or absence of cigarette smoke extract. Effects of isorhapontigenin and resveratrol on the release of IL-6 and chemokine (C-X-C motif) ligand 8 (CXCL8), and the activation of NF-κB, activator protein-1 (AP-1), MAPKs and PI3K/Akt/FoxO3A pathways were determined and compared with those of dexamethasone. The pharmacokinetic profiles of isorhapontigenin, after i.v. or oral administration, were assessed in Sprague-Dawley rats. KEY

resultsIsorhapontigenin concentration-dependently inhibited IL-6 and CXCL8 release, with IC CONCLUSIONS AND IMPLICATIONS: Isorhapontigenin, an orally bioavailable dietary polyphenol, displayed superior anti-inflammatory effects compared with resveratrol. Furthermore, it suppressed the PI3K/Akt pathway that is insensitive to corticosteroids. These favourable efficacy and pharmacokinetic properties support its further development as a novel anti-inflammatory agent for COPD.

Indexed as

Administration, OralAdrenal Cortex HormonesAgedAnimalsAnti-Inflammatory AgentsBiological AvailabilityCell SurvivalDose-Response Relationship, DrugEpithelial CellsFemaleHumansInflammationInjections, IntravenousMaleMolecular StructurePulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesAnti-Inflammatory AgentsisorhapontigeninResveratrolStilbenes

Identifiers

PMID28369685
PMCPMC5466528
OpenAlexW2601402626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.